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Abstract: BACKGROUNDPatients with diffuse midline gliomas (DMGs), including diffuse intrinsic pon-
tine glioma (DIPG), have dismal outcomes. We previously described the H3.3K27M mutation as a shared
neoantigen in HLA-A*02.01+, H3.3K27M+ DMGs. Within the Pacific Pediatric Neuro-Oncology Con-
sortium, we assessed the safety and efficacy of an H3.3K27M-targeted peptide vaccine.METHODSNewly
diagnosed patients, aged 3-21 years, with HLA-A*02.01+ and H3.3K27M+ status were enrolled in stratum
A (DIPG) or stratum B (nonpontine DMG). Vaccine was administered in combination with polyinosinic-
polycytidylic acid-poly-I-lysine carboxymethylcellulose (poly-ICLC) every 3 weeks for 8 cycles, followed
by once every 6 weeks. Immunomonitoring and imaging were performed every 3 months. Imaging was
centrally reviewed. Immunological responses were assessed in PBMCs using mass cytometry.RESULTSA
total of 19 patients were enrolled in stratum A (median age,11 years) and 10 in stratum B (median
age, 13 years). There were no grade-4 treatment-related adverse events (TRAEs). Injection site reac-
tion was the most commonly reported TRAE. Overall survival (OS) at 12 months was 40% (95% CI,
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levels of myeloid-derived suppressor cells had prolonged OS compared with their counterparts (P <
0.01). Immediate pretreatment dexamethasone administration was inversely associated with H3.3K27M-
reactive CD8+ T cell responses.CONCLUSIONAdministration of the H3.3K27M-specific vaccine was well
tolerated. Patients with H3.3K27M-specific CD8+ immunological responses demonstrated prolonged OS
compared with nonresponders.TRIAL REGISTRATIONClinicalTrials.gov NCT02960230.FUNDINGThe
V Foundation, the Pacific Pediatric Neuro-Oncology Consortium Foundation, the Pediatric Brain Tumor
Foundation, the Mithil Prasad Foundation, the MCJ Amelior Foundation, the Anne and Jason Farber
Foundation, Will Power Research Fund Inc., the Isabella Kerr Molina Foundation, the Parker Institute
for Cancer Immunotherapy, and the National Institute of Neurological Disorders and Stroke (NINDS),
NIH (R35NS105068).
DOI: https://doi.org/10.1172/JCI140378





Mueller, Sabine; Taitt, Jared M; Villanueva-Meyer, Javier E; Bonner, Erin R; Nejo, Takahide; Lulla, Rishi
R; Goldman, Stewart; Banerjee, Anu; Chi, Susan N; Whipple, Nicholas S; Crawford, John R; Gauvain,
Karen; Nazemi, Kellie J; Watchmaker, Payal B; Almeida, Neil D; Okada, Kaori; Salazar, Andres M;
Gilbert, Ryan D; Nazarian, Javad; Molinaro, Annette M; Butterfield, Lisa H; Prados, Michael D; Okada,
Hideho (2020). Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.
Journal of Clinical Investigation, 130(12):6325-6337.
DOI: https://doi.org/10.1172/JCI140378
2
Mass cytometry detects H3.3K27M-specific vaccine responses
in diffuse midline glioma
Sabine Mueller, … , Michael D. Prados, Hideho Okada
J Clin Invest. 2020;130(12):6325-6337. https://doi.org/10.1172/JCI140378.
  
Patients with diffuse midline gliomas (DMGs), including diffuse intrinsic pontine glioma (DIPG), have dismal outcomes.
We previously described the H3.3K27M mutation as a shared neoantigen in HLA-A*02.01+, H3.3K27M+ DMGs. Within
the Pacific Pediatric Neuro-Oncology Consortium, we assessed the safety and efficacy of an H3.3K27M-targeted peptide
vaccine.
Newly diagnosed patients, aged 3–21 years, with HLA-A*02.01+ and H3.3K27M+ status were enrolled in stratum A
(DIPG) or stratum B (nonpontine DMG). Vaccine was administered in combination with polyinosinic-polycytidylic acid-
poly-I-lysine carboxymethylcellulose (poly-ICLC) every 3 weeks for 8 cycles, followed by once every 6 weeks.
Immunomonitoring and imaging were performed every 3 months. Imaging was centrally reviewed. Immunological
responses were assessed in PBMCs using mass cytometry.
A total of 19 patients were enrolled in stratum A (median age,11 years) and 10 in stratum B (median age, 13 years).
There were no grade-4 treatment-related adverse events (TRAEs). Injection site reaction was the most commonly
reported TRAE. Overall survival (OS) at 12 months was 40% (95% CI, 22%–73%) for patients in stratum A and 39% (95%
CI, 16%–93%) for patients in stratum B. The median OS was 16.1 months for patients who had an expansion of […]
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Introduction
Diffuse midline gliomas (DMGs) are uniformly fatal pediatric 
brain cancers, and despite maximal therapy, survival outcomes 
remain dismal, with less than 10% of patients surviving beyond 
2 years (1). A hallmark of DMG is a set of recurrent mutations 
in genes encoding histone H3 variants including histones H3.3 
(H3F3A) and H3.1 (HIST1H3B and HIST1H3C) (2, 3). Recently, 
immunotherapy has garnered significant attention as a treatment 
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40% male) in stratum B (Table 1). DMGs in stratum B included 
7 thalamic tumors, 2 pontine-centered tumors that did not meet 
the imaging criteria for DIPGs, with extension into the cerebellum 
in both cases and the cervical spine in 1, and 1 spinal cord tumor 
located within the thoracic spine. The median time between tumor 
tissue collection and the start of radiation therapy (RT) was 17 days 
(range, 4–25 days) for patients in stratum A and 22 days (range, 
2–49 days) for those in stratum B, except for 1 patient, who had 
a biopsy performed after RT completion. The median time from 
completion of RT to the first vaccine was 39 days (range, 27–71 
days) for patients in stratum A and 39 days (range, 22–53 days) for 
patients in stratum B.
Treatment and safety. The median number of vaccinations 
administered was 7 (IQR = 4) and 5 (IQR = 4.5) for strata A and B, 
respectively. Treatment was generally well tolerated with no grade 
4 treatment-related adverse events (TRAEs). The most common 
TRAE was injection site reaction (Table 2). One patient from stra-
tum A experienced a regimen-limiting toxicity (RLT), presenting 
with signs and symptoms of meningitis. This patient was treated 
according to institutional guidelines with antibiotics and was hos-
pitalized until recovery. Blood and cerebrospinal fluid remained 
negative for meningitis, although the patient was started on antibi-
otics before sample collection. After recovery from this event, the 
patient was taken off the study, as TRAEs could not be excluded. 
There were no other instances of meningitis.
for cancers harboring tumor-specific neoantigens. We have iden-
tified a 10 mer peptide spanning position 26–35 (H3.3K27M
26–35
) of 
the H3.3K27M protein as an HLA-A*02:01–restricted cytotoxic T 
lymphocyte (CTL) epitope (4). Although most missense mutation–
derived neoantigens are unique to individual patients (5), a major-
ity of patients with DMG and more than 70% of patients with 
diffuse intrinsic pontine glioma (DIPG) have the H3.3K27M muta-
tion (6). The H3.3K27M-derived neoantigen epitope represents 
a valuable target, as it is not only tumor specific, but also K27M- 
mutant protein is present throughout all tumor nuclei in each of the 
47 cases evaluated by immunohistochemistry (7), suggesting that 
this may be a truncal mutation and less likely to lead to antigen loss– 
mediated escape from the tumor. Within this multicenter study 
conducted through the Pacific Pediatric Neuro-Oncology Con-
sortium (PNOC), we evaluated the safety, immunoreactivity, and 
efficacy of the synthetic H3.3K27M
26–35
 peptide in combination 
with the helper tetanus toxoid (TT) peptide and polyinosinic- 
polycytidylic acid-poly-I-lysine carboxymethylcellulose (poly-ICLC) 
adjuvant in patients with HLA-A*02:01+, H3.3K27M+ DMGs.
Results
Patient characteristics. From November 2016 until March 2019, a 
total of 19 eligible patients (median age, 11 years; IQR = 4.5 years; 
53% female, 47% male) were enrolled in stratum A and 10 eligi-
ble patients (median age, 13 years; IQR = 4.25 years; 60% female, 
Table 1. Patients’ baseline characteristics     
Characteristics Whole cohort (n = 29) DIPG (stratum A; n = 19) Other DMG (stratum B; n = 10)
Median age, yr (range) 11 (5–18) 11 (5–17) 12 (7–18)
Female, no. (%) 16 (55%) 10 (53%) 6 (60%)
Male, no. (%) 13 (45%) 9 (47%) 4 (40%)
Location
 Pons 21 19 2 (with cerebellar/spinal cord)
 Thalamic 6 0 7
 Spinal cord 2 0 1
Race 
 White 18 11 7
 African American 2 1 1
 Other (not available) 8 7 1
 Declined to identify 1 0 1
Ethnicity
 Non-Hispanic 23w 14 9
 Hispanic 3 3 0
 Not available/declined 3 2 1
Median no. of days from biopsy to start of RT (range)A 16 (2–49) 17 (4–25) 22 (2–49)
Median no. of days from end of RT to first vaccine (range) 40 (22–71) 39 (27–71) 39 (22–53)
Median no. of vaccines (range) 6 (1–11) 7 (2–11) 5 (1–11)
Positive H3.3K27M detection in plasma (% of available samples) 41/60 (68.3%) 29/42 (69.0%) 12/18 (66.7%)
PBMC immune profiling, median no. of samples per patient (range) 2 (0–5)B 2 (1–5) 2 (0–3)
Steroid use, no. (%) 13 (45) 9 (47) 4 (40)
Temozolomide use during RT, no. (%) 4 (13.8%) 3 (15.8%) 1 (10%)
Off-study treatment criteria
 Progression 27 18 9
 Lost to follow-up; withdrawal of consent 1 0 1
 Toxicity 1 1 0
AExcluding 1 patient who had biopsy after start of radiation therapy. BOne patient sample (PNOC007-16) lost due to technical difficulties during data acquisition.
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lected at multiple time points (n = 18), we analyzed longitudinal 
H3.3K27M-reactive CD8+ T cell frequencies (Supplemental Fig-
ure 4), which revealed that 7 (39%) patients met the criteria for an 
immunological response (Figure 1E). Among these patients, the 
median OS of overall immunological responders was 16.3 months 
(n = 7, 95% CI, 12.6–NA) compared with 9.9 months (n = 11, 95% 
CI, 9.0–NA) for nonresponders (P = 0.05, log-rank test) (Figure 
1F), with an estimated multivariate HR of 0.04 (95% CI, 0.004–
0.045, P < 0.01) (Supplemental Table 1). Further, immunological 
responders exhibited prolonged PFS (P = 0.05, log-rank test) com-
pared with nonresponders (Figure 1G). Patients with Tem (n = 6, 
P = 0.02, log-rank test) expansions also exhibited trends toward 
prolonged OS (Figure 1H and Supplemental Figure 5) and PFS (P 
= 0.06, log-rank test) compared with their counterparts (Figure 
1I and Supplemental Figure 6). These trends persisted when con-
trolling for stratum, as patients with DIPG showing overall immu-
nological responses had a median OS of 16.1 months (n = 6, 95% 
CI, 12.4–NA) compared with 10 months (n = 6, 95% CI, 9.5–NA) for 
nonresponders (P = 0.11, log-rank) (Supplemental Figure 7), with 
an estimated multivariate HR of 0.03 (95% CI, 0.001 to 1.960, 
P = 0.10) (Supplemental Table 1). Prolonged OS among patients 
with DIPG with Tem expansions (n = 6, P = 0.03, log-rank) further 
strengthened this association, while also being substantiated by 
prolonged PFS (P < 0.01, log-rank) relative to nonresponders (Sup-
plemental Figure 8). These corroborating survival trends did not 
persist when using the same longitudinal immunological response 
threshold for bulk CD8+ T cell phenotypic subtypes (Supplemental 
Clinical efficacy. The primary efficacy endpoint was the over-
all survival  at 12 months (OS12) of patients in stratum A. With a 
median follow-up time of 17.6 months, the OS12 rate was 44% 
(95% CI, 27%–75%) for patients in stratum A and 39% (95% CI, 
16%–93%) for those in stratum B (Figure 1A). The median progres-
sion-free survival (PFS) was 4.9 months (95% CI, 3–8.3 months) 
for stratum A and 3.5 months (95% CI, 3–NA) for stratum B (Fig-
ure 1B). One patient in stratum A had a positive response (partial 
response; PNOC007-25).
Detection, validation, clustering, and phenotyping of H3.3K27M- 
reactive CD8+ T cells. CyTOF-based immune analyses were con-
ducted on 28 of the total 29 patients enrolled in the study, in which 
H3.3K27M-reactive CD8+ T cells were detected using a conven-
tional CD8+ gating strategy (Supplemental Figure 1; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI140378DS1). H3.3K27M dextramer staining revealed negligible 
nonspecific staining on healthy donor–derived PBMCs (Figure 1C). 
CyTOF-based H3.3K27M-reactive CD8+ T cell detection was deter-
mined to be as sensitive as flow cytometry (Supplemental Figure 2). 
We observed that H3.3K27M-reactive CD8+ T cells were clustered 
on a t-distributed stochastic neighbor embedding (t-SNE) plot and 
grouped into 5 subpopulations (Supplemental Figure 3): early acti-
vated (Tea), stem cell memory (Tscm), effector (Teff), effector mem-
ory (Tem), and exhausted (Tex) phenotypes based on their aggregate 
phenotypic profiles (Figure 1D and Supplemental Figure 3).
Expansion of H3.3K27M-reactive CD8+ T cells is associated with 
a better prognosis. Of the patients from whom PBMCs were col-
Table 2. H3.3K27M/TT-related AEsA    
Stratum A (n = 19) Stratum B (n = 10)
Any AE 416 182
Any grade ≥Grade 3 Any grade ≥Grade 3
Injection site reaction 27 1 8 0
Gastrointestinal disorders (nausea, vomiting/diarrhea) 12 0 3 0
Fatigue 6 0 6 0
Fever 5 0 0 0
Nervous system related 
 Gait disturbance 4 1 1 0
 Muscle weakness 4 0 0 0
 Abducens paresis 3 0 0 0
 Ataxia 2 0 0 0
 Glossopharyngeal nerve paresis 4 0 0 0
 Headache 9 0 2 0
 Paresthesia 3 0 1 0
 Anorexia/weight loss 3 0 2 0
Blood disorders
 Neutropenia 3 1 1 0
 Lymphopenia 12 0 16 1
 Leukopenia 8 0 12 0
 Anemia 1 0 0 0
Laboratory results
 Hypokalemia 2 0 2 0
 ALT increase 5 0 0 0
 AST increase 4 0 0 0
AOccurring in more than 1 subject.
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(Supplemental Figure 17). However, we found that baseline MDSC 
frequencies did not correlate with tumor volume or age (Supple-
mental Figure 18). With regard to other immunoregulatory cell 
populations, CD4+ Tregs showed negligible associations with 
patient outcomes in the DIPG cohort (Supplemental Figure 19).
Dexamethasone administration is associated with lower rates of 
vaccine-specific CD8+ T cell responses and high MDSC levels among 
patients with DIPG. A total of 9 (47%) patients with DIPG received 
oral dexamethasone while in the study. Six of these patients com-
menced dexamethasone at least 3 days before baseline PBMC 
collection and exhibited a trend toward higher levels of baseline 
circulatory MDSCs, with 4 (67%) of the 6 patients on dexametha-
sone exhibiting circulatory MDSC frequencies above 5%, whereas 
3 (23%) of the 13 patients not receiving dexamethasone surpassed 
the same threshold (n = 19) (Figure 4A). Among patients receiv-
ing dexamethasone who were analyzed longitudinally, 3 (50% 
of 6 total) exhibited an overall decrease in H3.3K27M-reactive 
CD8+ T cells at the final collection time point relative to baseline, 
whereas only 1 (17% of 6 total) showed an overall expansion (Fig-
ure 4B and Supplemental Figure 20). Furthermore, patients with 
DIPG treated with dexamethasone at baseline had a median OS 
of 9.0 months (n = 6, 95% CI, 7.7–NA) compared with a median OS 
of 13.7 months (n = 13, 95% CI, 9.8–NA) for untreated patients (P < 
0.01, log-rank test) (Figure 4C). Although not statistically signifi-
cant, patients with DIPG treated with dexamethasone had a medi-
an PFS of 3.0 months (n = 6, 95% CI, 2.3–NA) compared with 5.3 
(n = 13, 95% CI, 4.1–NA) for untreated patients (P = 0.09, log-rank 
test) (Figure 4D). These trends persisted when combining strata A 
and B (Supplemental Figure 21).
Circulating tumor DNA analysis is not predictive of outcome. A 
cutoff threshold for positive circulating tumor DNA (ctDNA) was 
set at 0.001% on the basis of our previously described method (8), 
where sensitivity and specificity were fully described using spec-
imens from a large cohort of patients. At baseline, we collected 
plasma from 27 of 29 patients for quantification of H3.3K27M 
mutation (H3F3A c.83A>T) allelic frequency (MAF) (8–10). We 
detected circulating H3F3A c.83A>T tumor DNA H3.3K27M- 
specific ctDNA in 70.4% (n = 19 of 27) of the patients’ samples, but 
its presence at baseline or longitudinal fluctuation in abundance 
did not correlate with clinical outcomes (Supplemental Figures 22 
and 23) or immunological responses (unpublished observations).
Longitudinal assessment of immunological profiles in correlation 
with the clinical outcome of a patient with DIPG exhibiting a strong 
CD8+ response to vaccination. One patient enrolled in stratum A 
demonstrated a partial radiographic response at weeks 12 and 24 
(Figure 5A). Following a total of 9 vaccinations, the patient was 
taken off the study at week 36 because of clinical worsening but 
only a minor increase in tumor size, which did not meet radio-
graphic progression criteria based on a central imaging review. 
The patient underwent reirradiation 10 months after the first 
vaccine and never received dexamethasone. The patient has not 
received additional therapies and remains alive 19 months after 
the initial diagnosis (March 2020 cutoff). A longitudinal immu-
nological assessment revealed the time course–dependent expan-
sion and persistence of H3.3K27M-reactive CD8+ T cells (Figure 
5B). The continuously mounting T cell responses, along with the 
minor increase in tumor size by week 36, suggest a possibility of an 
Figures 9–12), suggesting that the survival benefit associated with 
the expansion of H3.3K27M-reactive CD8+ T cells is independent 
of overall T cell status. No association between H3.3K27M-reactive 
Tex expansion and patient outcomes was established (Supplemen-
tal Figures 5–8). The number of vaccines administered correlated 
with the longitudinal change in the percentage of H3.3K27M- 
reactive CD8+ T cells at the final time point analyzed relative to 
the percentage at baseline (Supplemental Figure 13). However, the 
median number of vaccines preceding immunological responses 
was 6 (IQR = 2) among responders, whereas the median number 
of total vaccines was also 6 (IQR = 4) among the nonresponders 
(Figure 2), suggesting that the number of vaccines is not the sole 
factor for separating responders from nonresponders.
Circulatory MDSC abundance at baseline functions as a prog-
nostic indicator for patients with DIPG. We identified myeloid 
cells using a conventional myeloid gating strategy (Figure 3A). Of 
these clusters, early myeloid-derived suppressor cells (E-MDSCs) 
(CD33+CD11b+HLA-DRloLinlo) and monocytic MDSCs (M-MD-
SCs) (CD33+CD11b+CD14+HLA-DRlo) could be distinguished 
using their phenotypic profiles (Supplemental Figure 14 and 
Supplemental Table 2). Patients were stratified into MDSClo and 
MDSChi cohorts (Figure 3B) for each subpopulation. Although 
baseline E-MDSC abundance did not correlate with improved 
outcomes (Supplemental Figures 15 and 16), M-MDSClo patients 
with DIPG had prolonged OS (P = 0.05, log-rank test) relative to 
OS for the M-MDSChi cohort of patients with DIPG (Supplemental 
Figure 16). MDSClo patients with DIPG had a median OS of 13.7 
months (95% CI, 9.8–NA) compared with 9.0 months (95% CI, 
7.7–NA) for MDSChi patients with DIPG (P < 0.01, log-rank test) 
(Figure 3C), with an estimated multivariate HR of 0.09 (95% CI, 
0.01–0.92, P = 0.04) (Supplemental Table 1). Further, MDSChi 
patients had a median PFS of 2.9 months (95% CI, 2.8–NA) com-
pared with 5.3 months (95% CI, 3.2–NA) for their counterparts (P 
= 0.03, log-rank test) (Figure 3D), with an estimated univariate 
HR of 3.1 (95% CI, 1.1–8.9, P = 0.04). Analyses incorporating both 
strata A and B did not yield significant findings (Supplemental Fig-
ure 15), whereas the limited sample size of stratum B prevented a 
robust cohort-specific survival analysis for these patients. These 
associations persisted when analyzing the outcomes of patients 
with the top and bottom quartile of baseline MDSC abundances 
Figure 1. Mass cytometry–based phenotyping of H3.3K27M-reactive 
CD8+ T cell subpopulations reveals associations between immunological 
responses and prolonged OS or PFS. (A and B) Kaplan-Meier survival curves 
contrasting the (A) OS and (B) PFS of patients enrolled in stratum A (red) 
and stratum B (blue) using log-rank tests. (C) Left: PBMCs derived from a 
healthy donor showed an absence of H3.3K27M dextramer staining. Right: 
The H3.3K27M dextramer exhibited sensitive detection of H3.3K27M- 
specific T cell receptor–transduced (TCR-transduced) CD8+ T cells. (D) 
Heatmap visualizing the relative expression (Z score) of subpopulation 
markers in patient-derived H3.3K27M-reactive CD8+ T cells. (E) Heatmap 
visualizing the patient-specific presence (blue) or absence (red) of an 
expansion of H3.3K27M-reactive CD8+ T cells in a subpopulation-specific 
manner. (F and G) Kaplan-Meier survival curves contrasting the (F) OS and 
(G) PFS of patients who had an immunological response (blue) compared 
with patients who did not (red) using log-rank tests. (H and I) Kaplan-Meier 
survival curves contrasting the (H) OS and (I) PFS of patients who had an 
expansion of effector memory H3.3K27M-reactive CD8+ T cells (blue) com-
pared with patients who did not (red) using log-rank tests.
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inflammation-associated imaging change in this case. This patient 
was classified as MDSClo among DIPG patients with total MDSC 
percentages of 2.6% (median = 4.2%), indicative of an improved 
prognosis among patients with DIPG, as our findings have reflected 
(Figure 3, C and D). Furthermore, this patient’s MDSC abundance 
did not increase above median levels until disease progression was 
identified at 36 weeks (Figure 5C).
Discussion
To our knowledge, this is the first multicenter trial assessing 
the safety and clinical efficacy of a vaccine directed toward 
the novel, shared neoantigen H3.3K27M
(27–36)
 in HLA-A*02:01+ 
patients with H3.3K27M+ DIPG or DMGs. The study demon-
strated safety of the regimen and supports the significance of 
immunological monitoring for the identification of predictive 
biomarkers. Moreover, clinical and immune data suggest that 
concurrent corticosteroid administration is associated with 
increased MDSC levels and lower vaccine efficacy.
The PNOC007 trial regimen demonstrated safety in regard to 
expected TRAEs. One child developed meningitis of unclear etiol-
ogy and recovered completely with standard treatment. It remains 
uncertain if this event was related to the vaccine, since no addi-
tional cases were identified. The PNOC007 treatment strategy 
did not improve the overall outcome of H3.3K27M+ patients with 
DMG, representing the worst prognostic group among patients 
with DMG (11). A recent analysis from the International and Euro-
pean DIPG registries reported a similar OS12 of 42.3% (95% CI, 
38.1%–44.1%) (1).
To our knowledge, this is the first trial in which individuals 
with DMG were enrolled on the basis of their  mutation status 
rather than tumor location. Outcome measures for these tumors 
remain a topic of ongoing prospective studies, but retrospective 
reviews show poor outcomes for these tumor location–specific sub-
groups. For example, a retrospective analysis of H3.3K27M+ DMGs 
enrolled in the German HIT-HGG registry revealed a median 
survival of 13 months among patients with thalamic tumors and 
4.8 months among those with tumors within the spine (11), simi-
lar to our results. To date, very few peptide vaccine–based strate-
gies have been reported for DIPGs or DMGs. We have previously 
reported a median survival of 12.7 months in patients with DIPG 
using a peptide vaccine strategy against IL-13Rα, EphA2, and sur-
vivin in combination with poly-ICLC (12). This trial used a strategy 
Figure 2. Individual patient study course. Depicted within this swimmer plot is the patient-specific timing of vaccine administration, dexamethasone 
treatment, detection of H3.3K27M-reactive T cell responses, tumor progression, and vital status (patients who withdrew consent were censored).
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similar to that for PNOC007, however, H3.3K27M status was not 
available and could have influenced outcomes.
Our cytometry by time of flight–based (CyTOF-based) anal-
yses of multiple immune subsets (13, 14) provided an opportunity 
to explore associations between expansion of H3.3K27M-reactive 
CD8+ T cell subsets and prolonged OS and PFS. Furthermore, 
this approach identified baseline circulatory MDSCs as a poten-
tial negative prognostic indicator for patients with DIPG. To our 
knowledge, this is the first CyTOF-based immunomonitoring 
platform used to evaluate epitope-specific CD8+ T cell responses 
in patients with cancer treated with peptide-based vaccines. 
Detection of this cell population was accomplished through HLA 
dextramer–based staining (15–17), as dextramers exhibit higher 
affinity and specificity for epitope-specific CD8+ T cell popula-
tions in comparison with conventional HLA tetramers (15, 17). 
Furthermore, an increased quantity of fluorophores conjugated 
to each dextramer allowed for increased binding to metal-conju-
gated secondary antibodies, resulting in higher resolution on both 
fluorophore- and lanthanide-based analytical platforms. This 
approach maximized sensitivity on the CyTOF platform, allowing 
for the comparable detection of H3.3K27M-reactive CD8+ T cells 
between flow and mass cytometry. This study validates CyTOF as 
a powerful tool for high-definition immunomonitoring of CD8+ T 
cell–based immunotherapies.
While other immune cell populations are the focus of inter-
est (18, 19) across the broad spectrum of cancer vaccines (20), 
CD8+ T cells remain the primary target population for develop-
ing an efficacious antitumor immunotherapy (21). Consistent 
Figure 3. Mass cytometry–based analysis of circulatory MDSCs reveals an association between baseline levels of MDSCs and shortened OS and PFS. (A) 
Representative gating strategy to identify myeloid cells from patient-derived PBMCs by mass cytometry. Cells that stained double-positive with iridium 
intercalator were identified as intact cells (far left). Cells with low cisplatin staining were identified as live cells (second from left). Cells that stained 
negative for CD45 or positive for CD3 were excluded (middle). Cells that stained positive for CD19 or positive for CD56 were excluded (second from right). 
Cells that stained positive for either CD11b or CD11c were identified as myeloid cells (far right). (B) Box plot shows the range of abundance of circulatory 
total MDSCs among patients  with DIPG classified as MDSClo or MDSChi. MDSC classifications were established on the basis of a median threshold. (C and 
D) Kaplan-Meier survival curves contrasting (C) OS and (D) PFS of DIPG patients with baseline circulatory MDSC levels above (red) and below (blue) the 
median threshold, as determined by log-rank tests.
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Figure 4. Administration of dexamethasone is positively associated with increased baseline MDSC levels and inversely associated with H3.3K27M- 
reactive CD8+ T cell responses and survival. (A) Box plot demonstrates the abundance of circulatory MDSCs at baseline among patients with DIPG treated 
with dexamethasone (n = 6) for at least 3 days prior to treatment relative to patients who did not receive dexamethasone (n = 13). (B) Waterfall plot depicts 
the overall longitudinal percentage change of H3.3K27M-reactive CD8+ T cells at the final time point analyzed relative to baseline for each patient with DIPG 
who was treated with dexamethasone. Yellow bars indicate the pre-treatment period; red bars indicate patients who received dexamethasone after com-
mencement of vaccination; and blue bars indicate patients who did not receive dexamethasone while in the study. (C and D) Kaplan-Meier survival curves 
contrasting the (C) OS and (D) PFS of patients with DIPG based on pretreatment dexamethasone administration, as determined by log-rank tests. 
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Corticosteroids are often administered to patients with DIPG 
or DMG to treat neurological dysfunction caused by tumor- or 
treatment-related edema. However, steroid dependency has 
been associated with a worse prognosis (36) and may negatively 
affect responses to immunotherapies (5). Consistent with recent 
preclinical in vitro and in vivo studies (37, 38), our data suggest a 
negative association between dexamethasone administration and 
the longitudinal expansion of vaccine-reactive CD8+ T cells, con-
sistent with a recent report (5). It is conceivable that tumor size 
and growth rate, which typically necessitate the use of cortico-
steroids, may confound our observations. Our data suggest a lack 
of association between the baseline tumor size and outcomes 
(Supplemental Figures 24 and 25), consistent with a recent study 
involving molecularly characterized DIPGs (39). However, given 
the small sample size, we cannot fully exclude that dexametha-
sone use, independent of its impact on vaccine efficacy, leads to 
worse outcomes. Nonetheless, this association calls for additional 
corroborative studies.
Key limitations of our study include the relatively small num-
ber of patients and longitudinal samples for immune phenotypic 
analyses and classification of immunological responses. Some 
study participants were lost to follow-up because of clinical wors-
ening of their disease before post-baseline PBMC collection, lim-
iting the availability of longitudinal samples to 62% (18 of 29) of 
the patients enrolled. Systematic evaluation of pre- and post-treat-
ment tumor microenvironment samples would have offered 
more insights on the vaccine’s effects, such as T cell infiltration 
as well as possible antigen loss and HLA downregulation. To date, 
post-treatment biopsy of DMGs remains a controversial topic in 
pediatric neuro-oncology (10, 40), and this limitation extended to 
our current study. At the time of submission, there were too few 
data to establish corroborations with CyTOF analyses (Supple-
mental Figures 26 and 27). Given the clinical information gained 
by pathologic assessment of post-treatment tumor biopsies, these 
should be considered in future trials to better understand the 
effect of our therapies.
In conclusion, our data reflect the safety of the regimen and 
highlight the encouraging roles of H3.3K27M-specific CD8+ T cell 
responses in these patients, warranting further studies targeting 
the H3.3K27M epitope. Such studies should focus on a vaccine 
regimen with anti–PD-1 therapy (based on expression of PD-1 on 
H3.3K27M-reactive CD8+ T cells) and adoptive transfer of T cells 
transduced with the H3.3K27M-reactive T cell receptor (4).
Methods
Study design. PNOC007 (ClinicalTrials.gov ID: NCT02960230) is a 
pilot trial assessing the safety, immunoreactivity, and efficacy of subcu-
taneous administration of the H3.3K27M synthetic peptide combined 
with helper TT peptide (Tet
A830
, PolyPeptide Group) (41, 42) emulsified 
in Montanide-ISA 51 VG (SEPPIC) and in combination with poly-ICLC 
(Hiltonol, Oncovir) in patients 3 to 21 years of age with newly diag-
nosed DIPG (stratum A) or nonpontine DMG, including spinal cord 
DMGs (stratum B). Key inclusion criteria were the confirmation of 
HLA-A*02:01+ status and the H3.3K27M mutation by Clinical Labora-
tory Improvement Amendments–approved (CLIA-approved) sequenc-
ing of tumor tissue as well as adequate organ function. Exclusion crite-
ria included known immune system disorders and treatment with other 
with this paradigm, the expansion of H3.3K27M-reactive CD8+ 
T cells, but not bulk CD8+ T cells, is suggestive of prolonged OS. 
Although this expansion provides insight into patient-specific 
immunological outcomes, it does not account for phenotypic com-
position or functionality. As peripheral Tex expansion has been 
correlated with poor prognoses in several cancer types (22, 23), 
the discrimination of this cell population, among others, is nec-
essary for a contextual assessment of immunological responses. 
Our data demonstrated no association between Tex expansion 
and favorable outcomes for patients. However, the expansion of 
H3.3K27M-reactive Tem cell subpopulations, which exhibit cyto-
lytic and tissue localization capabilities (24), was associated with 
clinical benefits among patients with DMG, consistent with pre-
vious reports (25–27).
One could raise a concern about whether the observed 
H3.3K27M-reactive CD8+ T cell responses merely reflect over-
all immune competency, which is often compromised in these 
patients. Our multivariate analysis on bulk CD8+ T cells suggested 
that this was not the case. Another line of concern is the possibil-
ity that patients with intrinsically slow-growing tumors may have 
received more vaccines than those with fast-growing tumors, 
thereby mounting higher levels of vaccine-reactive responses. 
Based on our analyses, this does not appear to be the case, as the 
median numbers of vaccines preceding immunological responses 
among responders was the same as the median number of total 
vaccines among nonresponders.
To date, there are no vaccine regimens that have been shown 
to be efficacious in CNS malignancies, as shown by randomized 
studies with adequate statistical powers. As we discussed in our 
recent review articles (28, 29), we recognize that underlying 
these failures are a number of mechanistic challenges, such as 
antigen-heterogeneity, local and systemic immunosuppression, 
and lack of adequate homing of effector immune cells. Although 
most tumor-specific antigens are expressed heterogeneous-
ly within the tumor (29), H3.3K27M appears to be uniformly 
expressed in the tumor tissue (7).
In terms of relevant immunosuppressive mechanisms, MDSCs 
have attracted particular interest not only as tumor promoters (30) 
but as entities antagonistic to peptide vaccine efficacy (31–33) in 
preclinical models. Our data reflected this, as MDSClo DIPG 
patients exhibited improved outcomes relative to their counter-
parts. It is also noteworthy that our data set showed an absence 
of associations between relative circulatory MDSC abundance 
and both the patient’s age and tumor volume. Although Tregs are 
important immunosuppressive cells, our analyses did not detect 
any association between Tregs and patient outcomes in the DIPG 
cohort, corroborating recent high-throughput analyses of PBMC 
samples in patients with glioblastoma (30). However, these results 
warrant caution. As cryopreservation and paraformaldehyde 
fixation are known to reduce polymorphonuclear MDSC viabil-
ity (34), E-MDSCs and M-MDSCs were used as proxies for total 
MDSC quantification. Our data did not establish a robust correla-
tion between baseline MDSC levels and longitudinal H3.3K27M- 
reactive CD8+ T cell frequencies, which may have been affected by 
the limited longitudinal samples available. Nevertheless, MDSCs 
represent an enticing target for combinatorial therapies (35) that 
maximize vaccine efficacy.
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of RT, and given every 3 weeks for the first 8 doses followed by every 6 
weeks (Supplemental Figure 28) on an outpatient basis for a maximum 
treatment period of 96 weeks. Vaccine was administered at the same 
location unless prevented by an adverse skin reaction. Concurrently, 
the adjuvant poly-ICLC was administered (30 μg/kg) intramuscularly 
within 2 cm of the vaccine injection site (43, 44). Follow-up data were 
collected through February 2020.
Study assessments. Patients were monitored by laboratory assess-
ments and physical examination. Tumor evaluations were performed 
with MRI at baseline and every 12 weeks. Blood was collected to assess 
ctDNA at baseline and every 12 weeks (10). PBMCs were collected at 
baseline and at weeks 12, 18, and 24, and then every 12 weeks there-
after for CyTOF-based immunomonitoring assessments.
investigational or anticancer agents with the exception of temozolomide 
(maximum 90 mg/m2/dose) during focal RT. Patients must have been 
either off systemic steroids or have been on a stable dose of dexameth-
asone not exceeding 0.1 mg/kg/day (maximum 4 mg/day). All patients 
were enrolled upon completion of focal RT.
Participating PNOC sites received the H3.3K27M synthetic pep-
tide vaccine combined with a TT peptide through a central supply 
from the Immunologic Monitoring and Cellular Products Laboratory 
at the University (IMCPL) of Pittsburgh. Pharmacists at each site 
were trained for the emulsification process and prepared each vaccine 
emulsion (300 μg/dose H3.3K27M synthetic peptide and 200 μg/dose 
TT peptide in Montanide). The vaccine was administered subcutane-
ously in either the arm or thigh, beginning 2–8 weeks after completion 
Figure 5. A patient who demonstrated a continued expansion of H3.3K27M-reactive CD8 + T cells. (A) MR images of a patient at baseline (left), week 12 
(second from left), week 24 (second from right), and week 36 (far right). The patient (PNOC007-25) was found to have local progression in week 36. (B) Plot 
shows the longitudinal percentage of H3.3K27M-reactive CD8+ T cell subpopulations among live PBMCs. (C) Plot depicts the longitudinal percentage of 
circulatory MDSC subsets among live PBMCs.
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outcomes of DIPG patients. Time-to-event analyses were calculated 
using the Kaplan-Meier method from the date of diagnosis to the 
date of censoring or death. Patients who withdrew consent were lost 
to follow-up or were still alive at the study cutoff date were censored 
for OS-based survival analyses. The log-rank and likelihood ratio tests 
were used for comparisons between groups in Kaplan-Meier and Cox 
proportional HR analyses, respectively. OS was used as the primary 
survival parameter for the Cox proportional HR multivariate analyses, 
which were conducted using nonconfounding variables (P > 0.10) as 
determined by Fisher’s exact test. A P value of less than 0.05 was con-
sidered statistically significant.
For stratum B, pilot OS data were obtained in this specific subpop-
ulation to support the design of the subsequent phase 2 trial (n = 10).
An overall immunological response to the vaccine was defined 
as at least a 25% post-vaccination increase in the proportion of 
H3.3K27M-reactive CD8+ T cells among total live PBMCs relative 
to baseline. An analogous approach was used for classifying the 
expansion of tSNE-stratified bulk and H3.3K27M-reactive CD8+ T 
cell subpopulations.
Patients were further classified by relative abundance of 
PBMC-derived MDSC subsets at baseline. Myeloid cells from all 
patients were pooled and stratified on a tSNE plot, revealing 32 
discrete clusters (Supplemental Figure 14), of which E-MDSC and 
M-MDSC subsets (51) were quantified. Patients were assigned 
MDSChi and MDSClo designations on the basis of the abundance 
of these cell populations relative to median levels at baseline. This 
approach was extrapolated to incorporate total (sum of E-MDSCs 
and M-MDSCs) MDSC levels.
Data analyses and visualization were performed using the ggplot2 
(52) and cytofkit (47) R packages.
Study approval. Prior to trial activation, the appropriate approvals 
were obtained from the relevant regulatory agencies, including the 
FDA, for use of the investigational new drug (IND no. 17070), as well 
as IRB approval from UCSF, Lurie Children’s Hospital of Chicago, Seat-
tle Children’s Hospital (Seattle, Washington, USA), Oregon Health & 
Science University, UCSD and Rady Children’s Hospital, Dana-Farber 
Cancer Institute, Children’s National Medical Center (Washington, 
DC, USA), Washington University in St. Louis, The Children’s Hospital 
Of Philadelphia (Philadelphia, Pennsylvania, USA), St. Jude Children’s 
Research Hospital (Memphis, Tennessee, USA), Nationwide Children’s 
(Columbus, Ohio, USA), Texas Children’s Hospital (Houston, Texas, 
USA), Primary Children’s Hospital (Salt Lake City, Utah, USA), and 
Children’s Minnesota (Minneapolis, Minnesota, USA). All study partic-
ipants or their parents provided informed consent and age-appropriate 
assent according to institutional IRB guidelines.
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Central imaging review. A central radiology review of all cases 
was conducted retrospectively using response assessment in neu-
ro-oncology (RANO) (45) criteria. MRI with T1 (with and without 
contrast enhancement), T2, and T2 fluid-attenuated inversion recov-
ery (FLAIR) was used to measure tumor size. Anterior-posterior 
and transverse dimensions were measured using the Horos (version 
3.0) software package. Progressive disease on MRI was defined as a 
greater than 25% increase in the sum of perpendicular diameters 
and/or development of new enhancing or nonenhancing lesions by a 
board-certified neuroradiologist.
Study endpoints. The study’s primary endpoints were the eval-
uation of safety for all patients and OS at 12 months for patients 
enrolled in stratum A. The exploratory endpoints included CyTOF-
based evaluation of H3.3K27M-reactive CD8+ T cell responses in 
PBMC samples, immunohistochemical analysis of available tumor 
tissue, and ctDNA analyses.
Safety. Adverse events (AEs), serious adverse events (SAEs), and 
RLTs were reported from vaccine initiation out to 30 days after the last 
study treatment. Grading was based on Common Terminology Crite-
ria for Adverse Events (CTCAE), version 4.0 (46). RLTs were defined 
as any grade-2 or greater autoimmune reaction; any grade-3 or greater 
hematologic or nonhematologic toxicity with the exception of lymph-
openia; any life-threatening event; and any other unexpected grade-2 
or greater neurological deficit that was related to the vaccine therapy 
and did not respond to a trial of dexamethasone or bevacizumab. AEs, 
SAEs, and RLTs were reviewed weekly by the study chairs and PNOC 
leadership according to PNOC standardized operating procedures 
for safety monitoring. The data monitoring and safety committee 
(DSMC) at UCSF monitored the trial.
An early stopping rule was implemented on the basis of RLT inci-
dences as follows: the first 3 patients in each stratum were observed 
for at least 12 weeks before the next set of patients were enrolled. If a 
RLT occurred in 1 of the first 3 patients, an additional 3 patients would 
be enrolled in that stratum and observed for at least 12 weeks. If fewer 
than 2 of the first 6 patients in each stratum experienced a RLT within at 
least 12 weeks of follow-up, the remaining patients would be enrolled. 
If a RLT occurred in 2 or more of the first 6 patients, accrual would 
be suspended. Therefore, with 6 patients enrolled, there was an 88% 
probability of detecting 1 or more RLTs with an underlying rate of 30%. 
There was a 74% probability of detecting 1 or more RLTs with an under-
lying rate of 20%. In stratum A, if all 19 patients were enrolled, there 
was an 86% probability of detecting 1 or more RLTs with an underlying 
rate of 10% and a 62% probability with an underlying rate of 5%.
Mass cytometric data processing. Data acquisition for H3.3K27M 
epitope–specific CD8+ T cell responses was conducted using the Flu-
idigm Helios CyTOF system at the UCSF Parnassus Flow Cytometry 
Core. The sensitivity and specificity of the HLA-A*02:01-H3.3K27 
dextramer (Immudex) were validated by positive staining of CD8+ 
T cells transduced with an H3.3K27M-specific T cell receptor (4) 
and negligible staining in nontransduced CD8+ T cells, respectively. 
H3.3K27M-reactive CD8+ T cells were pooled from all patients and 
displayed via a t-SNE plot in the cytofkit package (47).
Statistics for OS and immune responses. For stratum A, with a null 
hypothesis that OS12 is 40%, accrual of 19 patients provided 80% 
power with a target overall type I error of 0.05 to detect a 30% differ-
ence in OS12 using a 1-sided exact binomial test. A null OS12 rate of 
40% was chosen on the basis of prior studies (48–50) and review of 
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